Literature DB >> 27585966

Description and characterization of a penicillin-resistant Streptococcus dysgalactiae subsp. equisimilis clone isolated from blood in three epidemiologically linked patients.

Kurt Fuursted1, Marc Stegger2, Steen Hoffmann2, Lotte Lambertsen2, Paal Skytt Andersen2, Mette Deleuran3, Marianne Kragh Thomsen4.   

Abstract

BACKGROUND: During a 27 month period, we detected four incidents of penicillin-resistant (PR) Streptococcus dysgalactiae subsp. equisimilis (SDSE) isolated from blood cultures of three patients.
METHODS: The 4 PR-SDSE were compared phenotypically and molecularly (using WGS) with 36 penicillin-susceptible SDSE from blood cultures obtained in the same catchment area and time period.
RESULTS: Phylogenetic analysis showed that the four PR-SDSE belonged to a single clone and a possible epidemiological link between the three patients was identified to be a dermatology department. MICs of penicillin were determined to be 0.5-2 mg/L using Etest and 0.5 mg/L when tested by a broth microdilution method. The four PR-SDSE were unrelated to the 36 penicillin-susceptible isolates, which could suggest that they did not evolve locally from a susceptible clone, but have been introduced into the region. In silico genome-based resistome analysis revealed identical PBP mutations in all four isolates. We detected mutations in multiple PBPs, including two amino acid substitutions within the active sites of the transpeptidase domain of PBP2x (T341P and Q555E), which have also been detected in other PR streptococci. The remaining mutations were, however, all located outside the active-site motifs of the transpeptidase domain.
CONCLUSIONS: To the best of our knowledge, this is the first description and characterization of invasive PR-SDSE. The resistant isolates had several amino acid changes in various PBPs compared with penicillin-susceptible SDSE. The observation that SDSE also can become PR emphasizes the importance of performing antimicrobial susceptibility testing.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27585966     DOI: 10.1093/jac/dkw320

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  A Single Amino Acid Replacement in Penicillin-Binding Protein 2X in Streptococcus pyogenes Significantly Increases Fitness on Subtherapeutic Benzylpenicillin Treatment in a Mouse Model of Necrotizing Myositis.

Authors:  Randall J Olsen; Luchang Zhu; James M Musser
Journal:  Am J Pathol       Date:  2020-05-11       Impact factor: 4.307

2.  Reduced In Vitro Susceptibility of Streptococcus pyogenes to β-Lactam Antibiotics Associated with Mutations in the pbp2x Gene Is Geographically Widespread.

Authors:  James M Musser; Stephen B Beres; Luchang Zhu; Randall J Olsen; Jaana Vuopio; Hanne-Leena Hyyryläinen; Kirsi Gröndahl-Yli-Hannuksela; Karl G Kristinsson; Jessica Darenberg; Birgitta Henriques-Normark; Steen Hoffmann; Dominque A Caugant; Andrew J Smith; Diane S J Lindsay; David M Boragine; Timothy Palzkill
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

3.  A Chimeric Penicillin Binding Protein 2X Significantly Decreases in Vitro Beta-Lactam Susceptibility and Increases in Vivo Fitness of Streptococcus pyogenes.

Authors:  Randall J Olsen; Luchang Zhu; Regan E Mangham; Ahmad Faili; Samer Kayal; Stephen B Beres; James M Musser
Journal:  Am J Pathol       Date:  2022-07-15       Impact factor: 5.770

4.  Streptococcus pyogenes pbp2x Mutation Confers Reduced Susceptibility to β-Lactam Antibiotics.

Authors:  Kirsten S Vannice; Jessica Ricaldi; Srinivas Nanduri; Ferric C Fang; John B Lynch; Chloe Bryson-Cahn; Theodore Wright; Jeff Duchin; Meagan Kay; Sopio Chochua; Chris A Van Beneden; Bernard Beall
Journal:  Clin Infect Dis       Date:  2020-06-24       Impact factor: 9.079

5.  Age-related differences in clinical characteristics of invasive group G streptococcal infection: Comparison with group A and group B streptococcal infections.

Authors:  Yoshihiro Fujiya; Kayoko Hayakawa; Yoshiaki Gu; Kei Yamamoto; Momoko Mawatari; Satoshi Kutsuna; Nozomi Takeshita; Yasuyuki Kato; Shuzo Kanagawa; Norio Ohmagari
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

6.  Restricted Sequence Variation in Streptococcus pyogenes Penicillin Binding Proteins.

Authors:  Andrew Hayes; Jake A Lacey; Jacqueline M Morris; Mark R Davies; Steven Y C Tong
Journal:  mSphere       Date:  2020-04-29       Impact factor: 4.389

7.  Colonization of β-hemolytic streptococci in patients with erysipelas-a prospective study.

Authors:  Kristina Trell; Sofia Rignér; Marcelina Wierzbicka; Bo Nilson; Magnus Rasmussen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-10       Impact factor: 3.267

8.  Beta-Haemolytic Group A, C and G Streptococcal Infections in Southern Hungary: A 10-Year Population-Based Retrospective Survey (2008-2017) and a Review of the Literature.

Authors:  Márió Gajdács; Marianna Ábrók; Andrea Lázár; Katalin Burián
Journal:  Infect Drug Resist       Date:  2020-12-31       Impact factor: 4.003

9.  Integrative Reverse Genetic Analysis Identifies Polymorphisms Contributing to Decreased Antimicrobial Agent Susceptibility in Streptococcus pyogenes.

Authors:  Stephen B Beres; Luchang Zhu; Layne Pruitt; Randall J Olsen; Ahmad Faili; Samer Kayal; James M Musser
Journal:  mBio       Date:  2022-01-18       Impact factor: 7.867

10.  Large-scale genomic analysis of antimicrobial resistance in the zoonotic pathogen Streptococcus suis.

Authors:  Nazreen F Hadjirin; Eric L Miller; Gemma G R Murray; Phung L K Yen; Ho D Phuc; Thomas M Wileman; Juan Hernandez-Garcia; Susanna M Williamson; Julian Parkhill; Duncan J Maskell; Rui Zhou; Nahuel Fittipaldi; Marcelo Gottschalk; A W Dan Tucker; Ngo Thi Hoa; John J Welch; Lucy A Weinert
Journal:  BMC Biol       Date:  2021-09-07       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.